20

25

40

- 5 48. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 73.
- 10 49. The nucleic acid of claim 48 having the mutation C73R.
- 50. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 1 amino acid residue mutated to a Group 4 amino acid residue at position 101.
 - 51. The nucleic acid of claim 50 having the mutation P101S.

52. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having Group 1 amino acid residue mutated to a Group 3 amino acid residue at position 101.

53. The nucleic acid of claim 52 having the mutation P101Q.

- 54. The nucleic acid of claim 39, wherein the
 30 polynucleotide encodes a variant protein of the lovE
 protein having a valine amino acid residue mutated to
 another Group 2 amino acid residue at position 111.
- 55. The nucleic acid of claim 54 having the mutation 35 V111I.
 - 56. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 4 amino acid residue mutated to a Group 2 amino acid residue at position 133.
 - 57. The nucleic acid of claim 56 having the mutation S133L.

25

5

58. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having Group 3 amino acid residue mutated to a Group 2 amino acid residue at position 141.

10

- 59. The nucleic acid of claim 58 having the mutation E141V.
- 60. The nucleic acid of claim 39, wherein the
 15 polynucleotide encodes a variant protein of the lovE
 protein having a Group 3 amino acid residue mutated to a
 Group 5 amino acid residue at position 141.
- 61. The nucleic acid of claim 60 having the mutation 20 E141K.
 - 62. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 4 amino acid residue mutated to Group 6 amino acid residue at position 153.
 - 63. The nucleic acid of claim 62 having the mutation C153Y.
- 30 64. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 4 amino acid residue mutated to a Group 5 amino acid residue at position 153.
- 35 65. The nucleic acid of claim 64 having the mutation C153R.
- 66. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 4 amino acid residue mutated to a Group 1 amino acid residue at position 281.

- 5 67. The nucleic acid of claim 66 having the mutation T281A.
 - 68. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 3 amino acid residue mutated to a Group 2 amino acid residue at position 367.
 - 69. The nucleic acid of claim 68 having the mutation N367I.

15

10

70. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 3 amino acid residue mutated to a Group 6 amino acid residue at position 367.

20

- 71. The nucleic acid of claim 70 having the mutation N367Y.
- 72. The nucleic acid of claim 39, wherein the
 25 polynucleotide encodes a variant protein of the lovE
 protein having a Group 1 amino acid residue mutated to
 Group 4 amino acid residue at position 389.
- 73. The nucleic acid of claim 72 having the mutation 30 P389S.
 - 74. The nucleic acid of claim 39, wherein the polynucleotide encodes a variant protein of the lovE protein having a Group 1 amino acid residue mutated to a Group 2 amino acid residue at position 389.
 - 75. The nucleic acid of claim 74 having the mutation P389L.

40

35